Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
Eligibility criteria
Qualifiers
>= 18 years old
Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
Diagnosis of primary solid tumor and secondary involvement of the brain
If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter.
Disqualifiers
Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
Diagnosis of memory disorder pre-treatment.
Leptomeningeal disease or disease involving either hippocampus.
Trial design
Treatments tested in this trial
- Blood sample
- Brain magnetic resonance imaging (MRI)
- Brain Health Assessment
- Quality of Life (QoL) Questionnaire
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
1University of California, San Francisco94143, San FranciscoCalifornia, United States
Sponsors and collaborators
University of California, San Francisco
Lead sponsor
Source ClinicalTrials.gov